These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19715037)

  • 1. Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer.
    Coskun U; Alkis N; Celenkoglu G; Buyukberber S; Ozkan M; Camci C; Uner A; Er O; Aslan UY; Sevinc A; Tokluoglu S; Ozturk B; Yildiz R; Benekli M;
    J Natl Med Assoc; 2009 Aug; 101(8):761-4. PubMed ID: 19715037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
    Lee J; Park JO; Kim WS; Lee SI; Song SY; Lim DH; Choi SH; Heo JS; Lee KT; Lee JK; Kim K; Jung CW; Im YH; Lee MH; Kang WK; Park K
    Oncology; 2004; 66(1):32-7. PubMed ID: 15031596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.
    Feliu J; Mel R; Borrega P; López Gómez L; Escudero P; Dorta J; Castro J; Vázquez-Estévez SE; Bolaños M; Espinosa E; González Barón M;
    Ann Oncol; 2002 Nov; 13(11):1756-62. PubMed ID: 12419748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Multicenter phase II study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer].
    Nakamori S; Endo W; Ozato H; Shibata T; Takeda Y; Tohno K; Hasuike Y; Masutani S; Morimoto T; Doki Y; Mori M; Monden M
    Gan To Kagaku Ryoho; 2011 May; 38(5):789-92. PubMed ID: 21566438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas.
    Feliu J; Sáenz JG; Jaráiz AR; Castañón C; Cruz M; Fonseca E; Lomas M; Castro J; Jara C; Casado E; León A; Barón MG
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):419-26. PubMed ID: 16404636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective phase II trial of a combination of gemcitabine and UFT as first-line treatment in elderly patients with advanced non-small cell lung cancer.
    Baek JH; Kim H; Ahn JJ; Jegal Y; Seo KW; Ra SW; Park CR; Jung JP; Kim JW; Lee YJ; Cha HJ; Kwon WJ; Noh YJ; Oh S; Park JH; Min YJ
    Lung Cancer; 2012 Jun; 76(3):368-72. PubMed ID: 22192919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
    Nio Y; Hashimoto K; Yano S; Itakura M; Koike M; Yamaguchi K; Endo S; Tsuji M; Higami T; Maruyama R
    Oncol Rep; 2005 Aug; 14(2):401-8. PubMed ID: 16012722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma.
    Shin SJ; Kim H; Baek JH; Ahn JJ; Jegal Y; Seo KW; Park CR; Shin JK; Jung JP; Kim JW; Cha HJ; Kwon WJ; Jeong AK; Noh YJ; Park JH; Min YJ
    Lung Cancer; 2008 Apr; 60(1):83-91. PubMed ID: 18006180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of oral uracil-tegafur prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer.
    Tanno S; Nakano Y; Osanai M; Koizumi K; Izawa T; Habiro A; Mizukami Y; Yanagawa N; Fujii T; Okumura T; Kohgo Y
    Chemotherapy; 2006; 52(2):98-102. PubMed ID: 16567941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of gemcitabine, UFT and leucovorin in patients with advanced pancreatic cancer.
    Kim TW; Kang HJ; Ahn JH; Lee K; Chang HM; Kang YK; Lee JS
    Acta Oncol; 2002; 41(7-8):689-94. PubMed ID: 14651215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.
    Kim MK; Lee KH; Jang BI; Kim TN; Eun JR; Bae SH; Ryoo HM; Lee SA; Hyun MS
    Jpn J Clin Oncol; 2009 Jan; 39(1):49-53. PubMed ID: 19060295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer.
    Pericay Pijaume C; Escudero Emperador P; Bastús Piulats R; Campos Cervera JM; Esquerdo Galiana G; Gallén Castillo M; Alfaro Gamero J; Dotor Navarro E; Pisa Gatell A; Guasch Jordán I; Saigí Grau E;
    Clin Transl Oncol; 2011 Jan; 13(1):61-6. PubMed ID: 21239357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gemcitabine in combination with S-1 or UFT in patients with advanced pancreatic cancer].
    Sasajima J; Tanno S; Koizumi K; Nakano Y; Habiro A; Chiba A; Fujii T; Sugiyama Y; Nakamura K; Nishikawa T; Mizukami Y; Okumura T; Kohgo Y
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1657-61. PubMed ID: 19838023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Phase I/II study of combination chemotherapy with gemcitabine and UFT for advanced pancreatic cancer in a multi-center trial].
    Sumii T; Funakoshi A; Mizumoto K; Tanaka M; Arita Y; Ito T; Yamaguchi H; Ueki T; Sakai T; Miyahara T; Muranaka T; Igarashi H; Shinozaki H; Eriguchi N
    Gan To Kagaku Ryoho; 2008 Apr; 35(4):603-6. PubMed ID: 18408428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer.
    Yoshitomi H; Togawa A; Kimura F; Ito H; Shimizu H; Yoshidome H; Otsuka M; Kato A; Nozawa S; Furukawa K; Miyazaki M;
    Cancer; 2008 Nov; 113(9):2448-56. PubMed ID: 18823024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
    Lee KW; Kim YJ; Lee KH; Han SW; Kim TY; Oh DY; Im SA; Kim TY; Bang YJ; Choi IS; Kim JH
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):447-55. PubMed ID: 24947909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Retrospective analysis of uracil/tegafur, cyclophosphamide and gemcitabine compared with gemcitabine monotherapy in unresectable pancreatic cancer].
    Niki T; Yamamoto Y; Tsuda M; Horita K; Hirohata S; Nishisaki H
    Gan To Kagaku Ryoho; 2009 Feb; 36(2):273-8. PubMed ID: 19223744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.
    Song H; Han B; Park CK; Kim JH; Jeon JY; Kim IG; Kim HJ; Jung JY; Kim JH; Kwon JH; Jang G; Kim HY; Kim HS; Choi DR; Zang DY
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):845-52. PubMed ID: 23978987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
    Oh DY; Cha Y; Choi IS; Yoon SY; Choi IK; Kim JH; Oh SC; Kim CD; Kim JS; Bang YJ; Kim YH
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):527-36. PubMed ID: 19578850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin.
    El-Rayes BF; Zalupski M; Shields AF; Manza SG; LoRusso P; Philip PA
    Am J Clin Oncol; 2007 Apr; 30(2):101-5. PubMed ID: 17414457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.